American nonprofit medical center Mayo Clinic has partnered Dutch blockchain startup Triall to use its blockchain-integrated eClinical platform to advance clinical trial design and management of study data. The move is seen as a game changer and will lead to a global transformation towards proof-based decentralized clinical research.
The blockchain-powered platform will be used for a multi-center pulmonary arterial hypertension trial that includes 10 research sites and more than 500 patients across the United States, starting later this month.
Triall offers a modular and fully integrated suite of eClinical solutions that can be selected and configured based on each study's need and organizational context. The platform will support all core trial activities, including data capture, document management, study monitoring, and eConsent.
The platform, used in more than 7,000 clinical studies globally, applies blockchain to generate verifiable proof of the integrity of clinical trial data and leverages Self-Sovereign Identity (SSI) technologies to provide patients and research professionals with more ownership and control over their data, documents, and processes.
Triall's Verifiable Proof API will be applied to build immutable blockchain-registered audit trails as a new best practice for bolstering end-to-end clinical data integrity, from study start-up to study close-out and post-study activities.
The use of blockchain technology is expected to demonstrate an immutable public ledger audit trail to boost the verifiable data integrity of clinical trial. This immutable clinical trial-related data and chronology in the study process can be easily reviewed by Investigators, regulators and other trial stakeholders.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.